SMi’s inaugural Oligonucleotide Therapeutics and Delivery conference

SMi’s inaugural Oligonucleotide Therapeutics and Delivery conference

16 September - 17 September, 2020


+44 (0)20 7827 6000


Holiday Inn London - Kensington Forum, United Kingdom

Organized By:

SMi Group

+44 (0)20 7827 6000

King's Rd, Haslemere GU27 2QH, United Kingdom

About SMi’s inaugural Oligonucleotide Therapeutics and Delivery conference

Oligonucleotide therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules. They bring about the ability to affect targets that have been considered “non-draggable”. Heavy investments in oligonucleotide therapeutic discovery have created an emerging market need for drug delivery technologies.

SMi’s inaugural Oligonucleotide Therapeutics and Delivery conference is here to keep you updated. By bringing together leading representatives of pharmaceutical, biotechnology and academic institutions, the 2-day conference will provide first-hand information on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. From optimizing particle size to choosing the right nanocarrier systems, the conference will address delivery to non-hepatocyte cells such as cancerous tissues and overview the most successful platforms. Discussions will be centered around improving targeted therapy uniting the field’s biggest players to share their opinions.

Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.




Exhibitors Profile

•  Gain first-hand insight into oligonucleotide therapy clinical success up to date for improving development of novel agents in your pipeline
•  Listen to case studies presenting the latest candidates undergoing pre-clinical and clinical research
•  Deepen your understanding of crucial delivery methods and available platforms for non-hepatocytic delivery   
•  Collaborate with members of the oligonucleotide community leading pharmaceutical, biotechnology and academic representatives to maximise future opportunities

Visitors Profile

  • RNA Biology/Discovery
  • Novel Therapeutic Modalities
  • Innovation Technologies
  • C-level Scientific Executives
  • Formulation and Drug Delivery
  • Clinical Research and Development
  • Cell Biology

Register ( for this Event )

SSL Secure Connection